Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances

被引:7
作者
Hosaka, Shinya [1 ,2 ]
Murayama, Norie [1 ]
Satsukawa, Masahiro [2 ]
Uehara, Shotaro [1 ]
Shimizu, Makiko [1 ]
Iwasaki, Kazuhide [3 ]
Iwano, Shunsuke [1 ,4 ]
Uno, Yasuhiro [3 ]
Yamazaki, Hiroshi [1 ]
机构
[1] Showa Pharmaceut Univ, Machida, Tokyo 1948543, Japan
[2] Kaken Pharmaceut Co LTD, Shizuoka 4268646, Japan
[3] Shin Nippon Biomed Labs Ltd, Kainan, Wakayama 6420017, Japan
[4] Novartis Pharma KK, Tokyo 1068618, Japan
关键词
cynomolgus monkey; CYP2C19; substrates; loratadine; LIVER-MICROSOMES; METABOLISM; CYP2C19; IDENTIFICATION; INHIBITION; POLYMORPHISMS; TOLBUTAMIDE; CLOPIDOGREL; LORATADINE; WARFARIN;
D O I
10.1002/bdd.1991
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cynomolgus monkeys are used widely in preclinical studies as non-human primate species. The amino acid sequence of cynomolgus monkey cytochrome P450 (P450 or CYP) 2C19 is reportedly highly correlated to that of human CYP2C19 (92%) and CYP2C9 (93%). In the present study, 89 commercially available compounds were screened to find potential substrates for cynomolgus monkey CYP2C19. Of 89 drugs, 34 were metabolically depleted by cynomolgus monkey CYP2C19 with relatively high rates. Among them, 30 compounds have been reported as substrates or inhibitors of, either or both, human CYP2C19 and CYP2C9. Several compounds, including loratadine, showed high selectivity to cynomolgus monkey CYP2C19, and all of these have been reported as human CYP2C19 and/or CYP2C9 substrates. In addition, cynomolgus monkey CYP2C19 formed the same loratadine metabolite as human CYP2C19, descarboethoxyloratadine. These results suggest that cynomolgus monkey CYP2C19 is generally similar to human CYP2C19 and CYP2C9 in its substrate recognition functionality. Copyright (C) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:636 / 643
页数:8
相关论文
共 50 条
  • [31] Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19
    Toda, Akiko
    Uehara, Shotaro
    Inoue, Takashi
    Utoh, Masahiro
    Kusama, Takashi
    Shimizu, Makiko
    Uno, Yasuhiro
    Mogi, Masayuki
    Sasaki, Erika
    Yamazaki, Hiroshi
    XENOBIOTICA, 2018, 48 (07) : 720 - 726
  • [32] Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
    Lee, Jun-Beom
    Lee, Kyung-A
    Lee, Kyung-Yul
    YONSEI MEDICAL JOURNAL, 2011, 52 (05) : 734 - 738
  • [33] Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
    Imamura, Chiyo K.
    Furihata, Kenichi
    Okamoto, Shinichiro
    Tanigawara, Yusuke
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (04) : 408 - 413
  • [34] Interactions of omeprazole-based analogues with cytochrome P450 2C19: a computational study
    Li, Junhao
    Du, Hanwen
    Wu, Zengrui
    Su, Haixia
    Liu, Guixia
    Tang, Yun
    Li, Weihua
    MOLECULAR BIOSYSTEMS, 2016, 12 (06) : 1913 - 1921
  • [35] Cytochrome P450 2C9-CYP2C9
    Van Booven, Derek
    Marsh, Sharon
    McLeod, Howard
    Carrillo, Michelle Whirl
    Sangkuhl, Katrin
    Klein, Teri E.
    Altman, Russ B.
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (04) : 277 - 281
  • [36] Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: Application to troleandomycin and midazolam
    Grimsley, Aidan
    Gallagher, Richard
    Hutchison, Michael
    Pickup, Kathryn
    Wilson, Ian D.
    Samuelsson, Kristin
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (04) : 529 - 538
  • [37] Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel
    Nishiya, Y.
    Hagihara, K.
    Kurihara, A.
    Okudaira, N.
    Farid, N. A.
    Okazaki, O.
    Ikeda, T.
    XENOBIOTICA, 2009, 39 (11) : 836 - 843
  • [38] Menthol reduces the anticoagulant effect of warfarin by inducing cytochrome P450 2C expression
    Hoshino, Motohiro
    Ikarashi, Nobutomo
    Tsukui, Makoto
    Kurokawa, Asako
    Naito, Rina
    Suzuki, Midori
    Yokobori, Kohsuke
    Ochiai, Takumi
    Ishii, Makoto
    Kusunoki, Yoshiki
    Kon, Risako
    Ochiai, Wataru
    Wakui, Nobuyuki
    Machida, Yoshiaki
    Sugiyama, Kiyoshi
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 56 : 92 - 101
  • [39] Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies
    Murayama, Norie
    Yajima, Kanako
    Hikawa, Mikiko
    Shimura, Kanami
    Ishii, Yu
    Takada, Masaki
    Uno, Yasuhiro
    Utoh, Masahiro
    Iwasaki, Kazuhide
    Yamazaki, Hiroshi
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (02) : 116 - 121
  • [40] Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese
    Gu, Shuzhen
    Sun, Yan
    Han, Ruifa
    Wang, Lin
    Wang, Dongliang
    Wang, Jizuo
    Li, Xin
    BMC MEDICAL GENETICS, 2014, 15